NCT05364944 2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1 Terminated
Clinical Trials
10 trialsNCT03466216 2025-06-10
Phase 1 Study of AlphaMedixâ„¢ in Adult Subjects With SSTR (+) NET
Orano Med LLC
Phase 1 Terminated
NCT04893759 2025-04-17
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
Ascentage Pharma Group Inc.
Phase 1 Terminated
NCT02464007 2025-02-25
Study of rSIFN-co for Patients With Advanced Solid Tumors
Sichuan Huiyang Life Science and Technology Corporation
Phase 1 Terminated
NCT02943733 2022-09-23
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
University of Wisconsin, Madison
Phase 1 Terminated
NCT04258592 2022-08-12
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
Universitaire Ziekenhuizen KU Leuven
Phase 1 Terminated
NCT03014297 2019-08-08
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
University of Kentucky
Phase 1 Terminated
NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT01508104 2017-08-23
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
Phase 1 Terminated
NCT02359500 2017-05-03
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Icahn School of Medicine at Mount Sinai
Phase 1 Terminated